Search Results

Displaying Results 51-75 of 355 "'CLIN'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
CARsgen、固形がん治療向け世界初のCAR T細胞療法製品「Satri-cel」の承認を発表

Jun 24, 2026, 22:54 ET CARsgen、固形がん治療向け世界初のCAR T細胞療法製品「Satri-cel」の承認を発表

[3] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-32.[4] B.

More news about: CARsgen Therapeutics

카스젠, 고형암 대상 세계 최초 CAR T세포 치료제 사트리셀 승인 발표

Jun 23, 2026, 08:21 ET 카스젠, 고형암 대상 세계 최초 CAR T세포 치료제 사트리셀 승인 발표

[3] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-32.[4] B.

More news about: CARsgen Therapeutics

Jun 23, 2026, 03:00 ET AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

A, Cheng B, Seyger MMB, Murphy R, Stoll ML, Cordoro KM, van de Kerkhof P, Paller AS. The burden of pediatric psoriasis: a systematic review. Am J Clin Dermatol. Published online 2025. doi:10.1007/s40257-025-00965-5Bronckers IM, Paller AS, van Geel MJ, van de Kerkhof PC, Seyger MM. Psoriasis

More news about: AbbVie

Jun 23, 2026, 03:00 ET AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

A, Cheng B, Seyger MMB, Murphy R, Stoll ML, Cordoro KM, van de Kerkhof P, Paller AS. The burden of pediatric psoriasis: a systematic review. Am J Clin Dermatol. Published online 2025. doi:10.1007/s40257-025-00965-5Bronckers IM, Paller AS, van Geel MJ, van de Kerkhof PC, Seyger MM. Psoriasis

More news about: AbbVie

Delphi Diagnostics Announces New Publication Confirming EAI Predicts Benefit from Weekly Paclitaxel in HR+/HER2− Breast Cancer

Jun 22, 2026, 16:04 ET Delphi Diagnostics Announces New Publication Confirming EAI Predicts Benefit from Weekly Paclitaxel in HR+/HER2− Breast Cancer

Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial. Clin Cancer Res. 2026 May 26. doi: 10.1158/1078-0432.CCR-26-0177. Epub ahead of print. PMID: 42189890.About EAIDelphi Diagnostics'

More news about: Delphi Diagnostics Inc

科濟藥業全球首款治療實體瘤的CAR-T細胞治療產品愷力美®獲批上市

Jun 22, 2026, 07:42 ET 科濟藥業全球首款治療實體瘤的CAR-T細胞治療產品愷力美®獲批上市

[3] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-32.[4] B.

More news about: 科濟藥業

CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors

Jun 22, 2026, 07:20 ET CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors

[3] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-32.[4] B. Han, R. Zheng,

More news about: CARsgen Therapeutics

Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers

Jun 22, 2026, 07:00 ET Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers

Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas. J Clin Oncol 2025;43(27):3021–31.Brandon, S. et al. Risk factors and survival associated with lung cancer recurrence after curative-intent surgery:

More news about: Boehringer Ingelheim

Au salon européen VivaTech, Hon Hai Technology Group (Foxconn) consolide son leadership mondial dans le domaine des usines et des infrastructures d'IA

Jun 17, 2026, 08:18 ET Au salon européen VivaTech, Hon Hai Technology Group (Foxconn) consolide son leadership mondial dans le domaine des usines et des infrastructures d'IA

Considérée comme les débuts de Foxconn en Europe et comme un clin d'œil au plus grand événement européen consacré aux technologies et aux jeunes pousses, cette participation donne au principal fabricant mondial d'électronique

More news about: Hon Hai Technology Group (Foxconn)

Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia

Jun 16, 2026, 16:05 ET Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia

2013;14(6):488-492. Billiard M, Sonka K. Idiopathic hypersomnia. Sleep Med Rev. 2016;29:23-33. Trotti LM. Idiopathic hypersomnia. Sleep Med Clin. 2017;12(3):331-344. American Academy of Sleep Medicine. The International Classification of Sleep Disorders. Third Edition (ICSD-3). 2014. Khan

More news about: Jazz Pharmaceuticals plc

Brain-healthy Habits for Men

Jun 16, 2026, 10:45 ET Brain-healthy Habits for Men

Kris-Etherton PM, Pearson TA, Wan Y, et al. High-monounsaturated fatty acid diets lower both plasma cholesterol and triacylglycerol concentrations. Am J Clin Nutr. 1999;70(6):1009–1015.4. Petersen KS, Murphy J, Whitbread J, Clifton PM, Keogh JB. The Effect of a Peanut-Enriched Weight Loss Diet Compared

More news about: The Peanut Institute

Seen and Heard: ALLMYNE Champions Deaf and LGBTQ+ Representation Through Lead Sponsorship of Three-Time Gold Telly Award-Winning Film Passengers NYC

Jun 16, 2026, 10:11 ET Seen and Heard: ALLMYNE Champions Deaf and LGBTQ+ Representation Through Lead Sponsorship of Three-Time Gold Telly Award-Winning Film Passengers NYC

Sign Language on the world stage. The film also served as the closing film of the Seattle Deaf Film Festival and earned three nominations at Festival Clin d'Œil in Reims, France — for Best Feature Film, Best Writing, and Best Actor. Most recently, Passengers NYC screened at Austin, Texas's "ASL

More news about: ALLMYNE

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 13, 2026, 06:33 ET New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

https://www.cancer.org/cancer/types/multiple-myeloma/detection-diagnosis-staging/detection.html11 Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. J Clin Oncol. 2018;36(15):1479–1487. https://pmc.ncbi.nlm.nih.gov/articles/PMC6119139/12

More news about: Johnson & Johnson

Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer

Jun 12, 2026, 08:00 ET Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer

6 Yajur Arya et al. Updates in Small Cell Lung Cancer Treatment: No Longer Too Small to Ignore—A Review of Recent Therapeutic Advances. Am Soc Clin Oncol Educ Book 46, e524964(2026). DOI:

More news about: Jazz Pharmaceuticals plc

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Jun 11, 2026, 02:03 ET IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

2026.5 Tranekær S, Hansen DL, Frederiksen H. Epidemiology of Secondary Warm Autoimmune Haemolytic Anaemia-A Systematic Review and Meta-Analysis. J Clin Med. 2021 Mar 17;10(6):1244. doi: 10.3390/jcm10061244. PMID: 33802848; PMCID: PMC8002719.6 Cherif, H, Cai, Q, Crivera, C, Leon,

More news about: Johnson & Johnson

Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies

Jun 11, 2026, 01:00 ET Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies

[3] Siegel RL, Miller KD, et al. CA Cancer J Clin. 2020:70(1):7-30.[4] Lee YC, S Lheureux, et al. Curr Opin Obstet Gynecol. 2017:29:47-58.[5] Merck. European Commission Approves KEYTRUDA®

More news about: Roche

Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies

Jun 11, 2026, 01:00 ET Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies

[3] Siegel RL, Miller KD, et al. CA Cancer J Clin. 2020:70(1):7-30.[4] Lee YC, S Lheureux, et al. Curr Opin Obstet Gynecol. 2017:29:47-58.[5] Merck. European Commission Approves KEYTRUDA®

More news about: Roche

Children's Hospital of Philadelphia Study May Help Explain Why Some Children with Sepsis or Organ Failure Face a Harder Recovery

Jun 10, 2026, 15:01 ET Children's Hospital of Philadelphia Study May Help Explain Why Some Children with Sepsis or Organ Failure Face a Harder Recovery

CHOP Research Institute.Lindell et al. "Aberrant STAT signaling and T cell dysregulation define a targetable pediatric sepsis endotype." J Clin Invest. Online June 9, 2026. DOI: 10.1172/JCI202867.About Children's Hospital of Philadelphia: A non-profit, charitable organization,

More news about: Children's Hospital of Philadelphia

/C O R R E C T I O N -- MARTINI/

Jun 10, 2026, 06:28 ET /C O R R E C T I O N -- MARTINI/

synonymes de MARTINI et de la culture italienne.Le film s'ouvre sur Bailey qui s'arrête dans une voiture de course MARTINI originale des années 1970, clin d'œil à l'héritage légendaire de la marque en matière de course automobile. Accueilli par un Maestro énigmatique, il est officiellement introduit dans

More news about: MARTINI

Jun 09, 2026, 09:00 ET Estudo que acaba de ser publicado, no maior congresso de reumatologia da Europa, demonstra eficácia superior de nova molécula no tratamento da artrite psoriásica já na 16ª semana

Queiro R, et al. Arthritis Res Ther. 2022;24(1):1536.  Belinchón I, et al. J Dermatolog Treat. 2022;33(3):1661–97.  Behrens F, et al. Clin Rheumatol. 2021 Dec;40(12):4943-4954. doi: 10.1007/s10067-021-05891-5. Epub 2021 Sep 13.Você pode relatar uma reação adversa relacionada a um

More news about: UCB Biopharma

Whole-Body Spatial Intelligence Beyond Weight-loss: nference Advances Cardiometabolism Moat for Precision Peptide Medicines and Healthy Longevity

Jun 09, 2026, 05:13 ET Whole-Body Spatial Intelligence Beyond Weight-loss: nference Advances Cardiometabolism Moat for Precision Peptide Medicines and Healthy Longevity

https://www.medrxiv.org/content/10.64898/2026.04.23.26351609v1Venky Soundararajan, Karthik Murugadoss. Metabotyping using early body weight velocity in lung cancer patients treated with pembrolizumab. J Clin Oncol 44, e20527-e20527(2026).

More news about: nference

Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause

Jun 07, 2026, 11:00 ET Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause

tablets.Endnotes and ReferencesKapoor E, Collazo-Clavell ML, Faubion SS. Weight gain in women at midlife: a concise review. J Clin Endocrinol Metab. 2017;102(10):3732-3741.North American Menopause Society. The 2023 position statement of The North American Menopause Society.

More news about: Eli Lilly and Company

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

Jun 05, 2026, 10:00 ET Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

Nguyen MA, et al. Pathology. 2023 Aug;55(5):596-609.Jiang T, et al. Acta Pharm Sin B. 2021 Feb;11(2):355-372.Cocco E, et al. Nat Rev Clin Oncol. 2018 Dec;15(12):731-747.O'Haire S, et al. Sci Rep. 2023 Mar 13;13(1):4116.Qi C, et al. Int J Cancer. 2023 Dec 1;153(11):1916-1927.Vcare

More news about: Vcare PharmaTech

Jun 04, 2026, 17:06 ET Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress

Edition. Cephalalgia, 2018. 38(1): p. 1-211Burch, R.C., D.C. Buse, and R.B. Lipton, Migraine: epidemiology, burden, and comorbidity. Neurol Clin, 2019. 37(4): p. 631-649Lipton RB, Buse DC, Nahas SJ, Tietjen GE, Martin VT, Löf E, Brevig T, Cady R, Diener HC. Risk factors for migraine disease

More news about: H. Lundbeck A/S

Jun 04, 2026, 17:04 ET Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress

Edition. Cephalalgia, 2018. 38(1): p. 1-211Burch, R.C., D.C. Buse, and R.B. Lipton, Migraine: epidemiology, burden, and comorbidity. Neurol Clin, 2019. 37(4): p. 631-649Lipton RB, Buse DC, Nahas SJ, Tietjen GE, Martin VT, Löf E, Brevig T, Cady R, Diener HC. Risk factors for migraine disease

More news about: H. Lundbeck A/S

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.